Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
PLoS One. 2021 Jul 23;16(7):e0254895. doi: 10.1371/journal.pone.0254895. eCollection 2021.
Polycystic ovary syndrome (PCOS) is characterized by the presence of insulin resistance, and women with PCOS have high prevalence of gestational diabetes (GDM). Both conditions have been associated with increased risk for pregnancy complications such as preterm birth, preeclampsia and increased offspring birth weight. We aimed to estimate the prevalence of GDM in women with PCOS using both previous and new diagnostic criteria, and to analyse whether the risk of pregnancy complications increased with the presence of GDM. In addition, we aimed to assess the response to metformin treatment in PCOS women with GDM. We performed post-hoc analysis of three prospective, double blinded studies of altogether 791 pregnant women with PCOS randomized to either metformin or placebo treatment from first trimester to delivery. Glucose data allowing GDM classification after previous (WHO 1999) and new (WHO 2013 and Norwegian 2017) diagnostic criteria were available for 722 of the women. Complications such as preeclampsia, late miscarriage and preterm birth, birth weight and gestational age were correlated to the presence of GDM and metformin treatment. The prevalence of GDM was 28.3% (WHO 1999), 41.2% (WHO 2013) and 27.2% (Norwegian 2017). Having GDM already in first trimester associated with increased risk for late miscarriage (p<0.01). Having GDM according to newer criteria correlated to increased maternal age and BMI (p<0.001). Otherwise, having GDM (any criteria) correlated neither to the development of preeclampsia, nor to birth weight z-score or the proportion of offspring being large for gestational weight. Maternal age and BMI, parity and gestational weight gain, but not GDM or metformin treatment, were determinants for birth weight z-score. Conclusion: in pregnant women with PCOS, having GDM did not increase the risk for other pregnancy complications except for an increased risk for late miscarriage among those with GDM already in the first trimester.
多囊卵巢综合征(PCOS)的特征是存在胰岛素抵抗,而患有 PCOS 的女性患有妊娠糖尿病(GDM)的患病率很高。这两种情况都与妊娠并发症的风险增加有关,例如早产、子痫前期和增加的后代出生体重。我们旨在使用以前和新的诊断标准来估计患有 PCOS 的女性中 GDM 的患病率,并分析 GDM 的存在是否会增加妊娠并发症的风险。此外,我们旨在评估二甲双胍治疗对患有 GDM 的 PCOS 女性的反应。我们对三项前瞻性、双盲研究进行了事后分析,共纳入 791 名患有 PCOS 的孕妇,她们在孕早期至分娩期间被随机分配接受二甲双胍或安慰剂治疗。对于 722 名女性,有葡萄糖数据可根据以前(世界卫生组织 1999 年)和新(世界卫生组织 2013 年和挪威 2017 年)诊断标准对 GDM 进行分类。子痫前期、晚期流产和早产、出生体重和胎龄等并发症与 GDM 的存在和二甲双胍治疗相关。GDM 的患病率为 28.3%(世界卫生组织 1999 年)、41.2%(世界卫生组织 2013 年)和 27.2%(挪威 2017 年)。在孕早期就已经患有 GDM 与晚期流产的风险增加相关(p<0.01)。根据新的标准患有 GDM 与母亲年龄和 BMI 增加相关(p<0.001)。否则,无论使用哪种标准,患有 GDM 均与子痫前期的发生、出生体重 z 评分或大于胎龄儿的比例无关。母亲年龄和 BMI、产次和妊娠体重增加,但不是 GDM 或二甲双胍治疗,是出生体重 z 评分的决定因素。结论:在患有 PCOS 的孕妇中,除了在孕早期已经患有 GDM 的孕妇中晚期流产风险增加外,患有 GDM 并不会增加其他妊娠并发症的风险。